KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) R&D In Process (2016 - 2025)

Jazz Pharmaceuticals has reported R&D In Process over the past 10 years, most recently at $42.5 million for Q3 2025.

  • Quarterly R&D In Process changed N/A to $42.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $947.9 million through Dec 2025, up 9378.62% year-over-year, with the annual reading at $947.9 million for FY2025, 9378.62% up from the prior year.
  • R&D In Process was $42.5 million for Q3 2025 at Jazz Pharmaceuticals, down from $905.4 million in the prior quarter.
  • Over five years, R&D In Process peaked at $905.4 million in Q2 2025 and troughed at $1.0 million in Q1 2023.
  • The 4-year median for R&D In Process is $30.2 million (2023), against an average of $137.6 million.
  • Biggest five-year swings in R&D In Process: plummeted 64.0% in 2023 and later soared 900.0% in 2024.
  • Tracing JAZZ's R&D In Process over 4 years: stood at $50.0 million in 2022, then plummeted by 64.0% to $18.0 million in 2023, then crashed by 44.44% to $10.0 million in 2024, then soared by 325.0% to $42.5 million in 2025.
  • According to Business Quant data, R&D In Process over the past three periods came in at $42.5 million, $905.4 million, and $10.0 million for Q3 2025, Q2 2025, and Q1 2024 respectively.